obesity research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
There are also dimeric alkaloids formed from two distinct monomers, such as the vinca alkaloids vinblastine and vincristine, which are formed from the coupling of catharanthine and vindoline. The newer semi-synthetic chemotherapeutic agent vinorelbine is used in the treatment of non-small-cell lung cancer. It is another derivative dimer of vindoline and catharanthine and is synthesised from anhydrovinblastine, starting either from leurosine or the monomers themselves.
== History in the West == The earliest appearance in Western documents is probably in the Portuguese Nippo Jisho (1603), as Vacame. In 1867 the word wakame appeared in an English-language publication, A Japanese and English Dictionary, by James C. Hepburn. Starting in the 1960s, the word wakame started to be used widely in the United States, and the product (imported in dried form from Japan) became widely available at natural food stores and Asian-American grocery stores, due to the influence of the macrobiotic movement, and in the 1970s with the growing number of Japanese restaurants and sushi bars.
==== Insulin ==== In October 1920, Frederick Banting took interest in carbohydrate metabolism while preparing a talk he was to give his physiology students at Western University in London, Ontario. He encountered an article by Moses Barron which reported an autopsy of a patient whose pancreatic stone had obstructed the main pancreatic duct, but most of the islet cells had survived intact. Banting wrote a note on October 31 of that year describing his thinking: "Ligate pancreatic ducts of dog. Keep dogs alive till acini degenerate leaving Islets. Try to isolate the internal secretion of these to relieve glycosurea [sic]" On November 8, 1920, Banting met with John Macleod, a senior professor of physiology at the University of Toronto, to ask if he might mount a research project on the internal secretion of the pancreas. Banting lacked experience in physiological research and had superficial knowledge of the subject. Nonetheless, Macleod took some interest and accepted Banting's request to work in his lab. On account of what may have interested Macleod, Michael Bliss considers the following:Speculation is in order here and is permissible because we have some idea of Macleod's knowledge of the literature. Whether he and Banting were discussing grafting or extracting, what must have appealed to Macleod as "never having been tried before" was the idea of somebody experimenting with degenerated or atrophied pancreas.
=== Iodine deficiency === Among humans with dietary iodine deficiency, the thyroid will not be able to make thyroid hormones. The lack of thyroid hormones will lead to decreased negative feedback on the pituitary gland, leading to increased production of thyroid-stimulating hormone, which causes the thyroid to enlarge in a medical condition called endemic colloid goitre. This has the effect of increasing the thyroid's ability to trap more iodide, compensating for the iodine deficiency and allowing it to produce adequate amounts of thyroid hormone.
Sources: en.wikipedia.org
== Applications == Currently, it is used industrially to verify, with a high throughput, the concentrations of brominated flame retardants (BFR) in plastics in compliance with the European Union's RoHS (Restriction of Hazardous Substances) regulation in place since 2006. The banned molecules include PBB and PBDE, whose concentration should not exceed 0.1% w/w. IAMS has also been used to analyze diesel exhaust particles, in ceramic processing, and in critical silicon etching during semiconductor manufacturing.
After Reagan's military buildup, the Soviet Union did not respond by further building its military, because the enormous military expenses, along with inefficient planned manufacturing and collectivized agriculture, were already a heavy burden for the Soviet economy. At the same time, Saudi Arabia increased oil production, even as other non-OPEC nations were increasing production. These developments contributed to the 1980s oil glut, which affected the Soviet Union as oil was the main source of Soviet export revenues. Issues with command economics, oil price decreases and large military expenditures gradually brought the Soviet economy to stagnation.
=== Improved mine safety === An ultrasonic bolt elongation monitor developed by a NASA scientist for testing tension and high-pressure loads on bolts and fasteners has continued to evolve over the past three decades. Today, the same scientist and Luna Innovations are using a digital adaptation of this same device for non-destructive evaluation (NDE) of railroad ties, groundwater analysis, radiation, and as a medical testing device to assess levels of internal swelling and pressure for patients with intracranial pressure and compartment syndrome, a painful condition that results when pressure within muscles builds to dangerous levels.
Border control policies typically require travellers to present valid travel documents to ascertain their identity, nationality, permanent residence status, and eligibility to enter a given jurisdiction. The most common form of travel document is the passport, a booklet-form identity document issued by national authorities or the governments of certain subnational territories containing an individual's personal information as well as space for the authorities of other jurisdictions to affix stamps, visas, or other permits authorising the bearer to enter, reside, or travel within their territory. Certain jurisdictions permit individuals to clear border controls using identity cards, which typically contain similar personal information.
polymorphism 1. In genetics, the regular and simultaneous existence of two or more discontinuous alleles or genotypes in the same population where the frequency of each allele is greater than can be explained by recurrent mutation alone, typically occurring in more than 1 percent of the population's individuals. An example is the different human blood types (A, B, AB, and O). 2. In chemistry, the existence of the same substance in two or more different crystalline forms.
Sources: en.wikipedia.org
Magnetohydrodynamics (MHD; also called magnetofluid dynamics or hydromagnetics) is a model of electrically conducting fluids that treats all types of charged particles together as a single continuous fluid. It is primarily concerned with the low-frequency, large-scale magnetic behavior of plasmas and liquid metals and has applications in multiple fields, including space physics, geophysics, astrophysics, and engineering.
In the above equations, cE and cI are total concentrations of all polypeptides and all polynucleotides, φx and φy are dilution fluxes, ki is the production rate of polypeptide Ei translated from the polynucleotide Ii, and fi is the production rate of polynucleotide Ii synthesised by the complex IiEi-1 (through replication and polymerization). Coupling nucleic acids with proteins in such a model of hypercycle with translation demanded the proper model for the origin of translation code as a necessary condition for the origin of hypercycle organization. At the time of hypercycle theory formulation, two models for the origin of translation code were proposed by Crick and his collaborators. These were models stating that the first codons were constructed according to either an RRY or an RNY scheme, in which R stands for the purine base, Y for pyrimidine, and N for any base, with the latter assumed to be more reliable. Nowadays, it is assumed that the hypercycle model could be realized by utilization of ribozymes without the need for a hypercycle with translation, and there are many more theories about the origin of the genetic code.
==== Micrococcus lysodeikticus ==== By the measurement of decrease in turbidity of M. lysodeikticus by incubating it with lysozyme, enzymatic activity can be evaluated. 7.5 μL of 0.1 - 1 mg/mL proteins is added to 200 μL of M. lysodeikticus at its optical density (OD) of 1.7 AU, and the mixture is measured at 450 nm periodically for reaction rate calculation. On the contrary to the result from glycol chitosan enzymatic activity, the increasing degree of PEGylation decreased the enzymatic activity. This difference in the trend of the enzymatic activity can be due to PEGylation to free lysine causing steric hindrance and subsequently preventing from forming enzyme-substrate complex in the case of reacting with macromolecule, such as M. lysodeikticus.
== External links == Guidance for the Care of Human Remains in Museums, published by the Department for Culture, Media and Sport (England, Wales, and Northern Ireland) Introduction to human remains in museums, published by Museum Galleries Scotland Recommendations for the Care of Human Remains in Museums and Collections, published by Deutscher Museumsbund (German Museums Association) Full Wellcome Trust policy on the care of human remains in museums and galleries
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.